| Source: |
Insect Cell |
| Molecular Weight: |
Approximately 23.0 kDa on SDS-PAGE under reducing conditions, containing 205 amino acids, and a molecular mass about 47.9 kDa homodimer under non-reducing conditions (Molecular size on SDS-PAGE will appear at approximately 50-80 kDa). |
| AA Sequence: |
QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC |
| Purity: |
> 95% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is 0.04‑0.2 μg/mL in the presence of 50 ng/mL of Recombinant Human BMP‑4. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH7.4, 5% trehalose, 0.02%Tween-20. |
| Endotoxin: |
Less than 0.1 EU/μg of rHuNoggin, Insect Cell as determined by LAL method. |
| Reconstitution: |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 10 mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Background: |
Noggin, encoded by the NOG gene, was initially identified in Xenopus as a protein that induces secondary axis formation in frog embryos. It functions by inhibiting TGF-β family ligands, thereby preventing them from binding to their respective receptors. Originally characterized as an antagonist of BMP-4, Noggin has since been found to modulate the activities of other BMPs such as BMP-2, BMP-7, BMP-13, and BMP-14. It exhibits pleiotropic effects during both early development and later stages.
Mouse knockout studies indicate that Noggin is crucial for various developmental processes, including neural tube fusion and joint formation. Mutations affecting evolutionarily conserved amino acid residues of Noggin have been linked to proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1), highlighting its clinical relevance.
Comparative analysis shows that mature human Noggin shares high sequence identity with Noggin from other species: 99% with mouse, rat, and bovine; 98% with equine; and 89% with chicken Noggin. |
